GERN Stock Price, Geron Corp Quote, Chart

Market Summary

USD3.44-0.20

Market Closed

-5.49%

GERN Stock Price

View Fullscreen

GERN RSI Chart

GERN Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-10.2

Price/Sales (Trailing)

7.9K

Price/Free Cashflow

-11.14

GERN Price/Sales (Trailing)

GERN Profitability

Return on Equity

-74.26%

Return on Assets

-46.72%

Free Cashflow Yield

-8.97%

GERN Fundamentals

GERN Revenue

Revenue (TTM)

237.0K

Rev. Growth (Yr)

-77.67%

Rev. Growth (Qtr)

-85.98%

GERN Earnings

Earnings (TTM)

-184.1M

Earnings Growth (Yr)

-21.9%

Earnings Growth (Qtr)

-16%

Breaking Down GERN Revenue

Last 7 days

3.3%

Last 30 days

2.4%

Last 90 days

74.6%

Trailing 12 Months

74.6%

How does GERN drawdown profile look like?

GERN Financial Health

Current Ratio

3.16

Debt/Equity

0.14

Debt/Cashflow

-4.79

GERN Investor Care

Shares Dilution (1Y)

7.34%

Diluted EPS (TTM)

-0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	494.0K	450.0K	317.0K	237.0K
2022	1.4M	1.3M	1.5M	596.0K
2021	338.0K	402.0K	403.0K	1.4M
2020	1.5M	397.0K	374.0K	253.0K
2019	3.3M	3.7M	2.8M	2.6M
2018	922.0K	1.5M	2.4M	2.5M
2017	6.0M	5.9M	968.0K	1.1M
2016	28.8M	21.3M	13.7M	6.2M
2015	1.2M	1.1M	36.3M	36.4M
2014	992.0K	1.2M	1.2M	1.2M
2013	2.2M	2.2M	1.7M	1.3M
2012	2.2M	1.9M	2.3M	2.7M
2011	4.2M	3.6M	3.3M	2.4M
2010	0	2.3M	3.0M	3.6M
2009	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Geron Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 29, 2023	aggarwal gaurav	acquired	-	-	1,970	-
Dec 29, 2023	molineaux susan	acquired	-	-	6,220	-
Dec 29, 2023	spiegel robert j.	acquired	-	-	3,406	-
Sep 29, 2023	spiegel robert j.	acquired	-	-	3,390	-
Sep 29, 2023	molineaux susan	acquired	-	-	6,191	-
Aug 24, 2023	o'farrell elizabeth g.	bought	15,064	2.28	6,607	-
Aug 24, 2023	o'farrell elizabeth g.	bought	15,000	2.28	6,579	-
Jun 30, 2023	kapur anil	acquired	15,436	2.04	7,567	evp, corp strategy & cco
Jun 30, 2023	molineaux susan	acquired	-	-	4,088	-
Jun 30, 2023	spiegel robert j.	acquired	-	-	2,239	-

Which funds bought or sold GERN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	High Net Worth Advisory Group LLC	unchanged	-	30,369	84,216	0.03%
Apr 11, 2024	Douglas Lane & Associates, LLC	sold off	-100	-149,599	-	-%
Apr 11, 2024	Allied Investment Advisors, LLC	unchanged	-	24,942	69,165	0.02%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 04, 2024	MOODY NATIONAL BANK TRUST DIVISION	reduced	-0.76	153,817	432,449	0.03%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-4.00	844	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	10.96	2,213	23,413	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.18	3,772,730	60,271,300	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	80.73	5,960,040	13,421,300	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	2.46	10,434	537,339	-%

Are Funds Buying or Selling GERN?

Are funds buying GERN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GERN

No. of Funds

Unveiling Geron Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	5.45%	29,583,449	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	55,145,502	SC 13G/A
Feb 13, 2024	vanguard group inc	5.26%	28,564,574	SC 13G
Jan 26, 2024	blackrock inc.	7.8%	42,172,679	SC 13G/A
Jan 22, 2024	state street corp	4.72%	25,625,606	SC 13G/A
Feb 14, 2023	vivo opportunity, llc	4.3%	26,901,882	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	48,423,211	SC 13G/A
Feb 03, 2023	growth equity opportunities 17, llc	-	0	SC 13D/A
Feb 01, 2023	state street corp	5.17%	19,712,189	SC 13G
Jan 31, 2023	blackrock inc.	7.2%	27,261,135	SC 13G/A

Recent SEC filings of Geron Corp

View All Filings

Date Filed	Form Type	Document
Mar 27, 2024	ARS	ARS
Mar 27, 2024	DEF 14A	DEF 14A
Mar 27, 2024	DEFA14A	DEFA14A
Mar 20, 2024	424B5	Prospectus Filed
Mar 20, 2024	8-K	Current Report
Mar 19, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report
Feb 16, 2024	4	Insider Trading

Peers (Alternatives to Geron Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Geron Corp News

Latest updates

Geron Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-86.0%	23.00	164	29.00	21.00	103	297	73.00	123	1,040	109	107	137	50.00	108	43.00	52.00	171	131	1,113	1,162	375
Operating Expenses	13.7%	54,312	47,776	51,980	40,113	42,054	40,245	28,049	28,798	32,022	25,783	28,996	28,591	23,316	20,123	16,805	16,922	30,179	16,103	15,325	11,358	9,964
S&GA Expenses	16.6%	21,401	18,350	16,490	12,894	13,844	15,642	7,443	6,699	7,872	7,256	7,059	7,478	7,088	6,510	5,960	6,120	5,256	4,994	5,191	5,452	4,883
Interest Expenses	12.3%	2,321	2,066	2,003	1,922	2,005	1,817	1,581	1,479	1,135	1,058	804	743	754	6.00	-	-	-	-	-	-	-
Net Income	-16.0%	-51,973	-44,805	-49,227	-38,122	-42,635	-41,051	-28,117	-30,098	-32,017	-26,697	-29,574	-27,824	-23,787	-19,651	-15,824	-16,355	-29,070	-15,180	-14,239	-10,059	-7,300
Net Income Margin	-40.9%	-776.91*	-551.38*	-380.08*	-303.49*	-238.09*	-85.64*	-86.94*	-85.85*	-83.35*	-267.70*	-250.84*	-257.65*	-	-	-	-	-	-	-	-	-
Free Cashflow	19.7%	-41,002	-51,031	-29,803	-46,737	-35,321	-29,753	-28,712	-34,024	-22,271	-22,934	-17,814	-32,744	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.6%	394	413	415	425	191	233	238	198	226	229	252	259	271	286	275	143	166	164	166	176	185
Current Assets	1.9%	341	335	377	387	180	222	227	176	187	179	202	215	200	232	221	134	142	142	155	156	166
Cash Equivalents	128.0%	70.00	31.00	57.00	113	57.00	61.00	76.00	31.00	35.00	29.00	57.00	32.00	10.00	45.00	23.00	20.00	14.00	21.00	18.00	7.00	11.00
Net PPE	-4.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Liabilities	6.5%	146	137	128	119	111	108	105	102	100	-	-	-	60.00	53.00	-	-	30.00	-	-	-	-
Current Liabilities	20.9%	108	89.00	73.00	44.00	77.00	83.00	47.00	47.00	46.00	38.00	37.00	29.00	31.00	24.00	19.00	17.00	28.00	12.00	9.00	6.00	8.00
Long Term Debt	17.5%	35.00	30.00	41.00	51.00	30.00	38.00	45.00	50.00	50.00	35.00	34.00	24.00	24.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	17.5%	35.00	30.00	41.00	51.00	30.00	38.00	45.00	50.00	50.00	35.00	34.00	24.00	24.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-14.7%	248	291	298	326	80.00	108	142	97.00	126	152	176	201	211	233	251	121	135	152	157	169	178
Retained Earnings	-3.4%	-1,597	-1,545	-1,500	-1,451	-1,413	-1,371	-1,329	-1,301	-1,271	-1,239	-1,213	-1,183	-1,155	-1,131	-1,112	-1,096	-1,080	-1,050	-1,035	-1,021	-1,011
Additional Paid-In Capital	0.4%	1,845	1,837	1,800	1,777	1,493	1,479	1,472	1,400	1,398	1,391	1,389	1,384	1,366	1,364	1,362	1,217	1,215	1,203	1,192	1,191	1,189
Shares Outstanding	-6.0%	545	580	547	544	390	405	404	332	328	327	327	324	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,395	-	-	-	503	-	-	-	377	-	-	-	516	-	-	-	262	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.5%	-40,938	-50,839	-29,601	-46,365	-35,181	-29,582	-28,642	-33,974	-22,168	-22,840	-17,814	-32,734	-12,614	-15,449	-12,395	-26,194	-10,366	-11,980	-8,745	-12,738	-3,010
Share Based Compensation	-38.7%	4,416	7,204	3,945	2,961	2,188	2,063	2,058	1,692	2,305	2,008	1,973	1,794	1,852	1,768	1,707	1,568	1,650	1,569	1,434	1,426	1,594
Cashflow From Investing	1109.1%	47,569	-4,714	-44,444	-178,733	18,988	9,842	2,810	30,427	8,365	-5,406	30,905	38,083	-21,836	13,564	-129,206	32,158	-7,013	6,037	19,412	8,964	848
Cashflow From Financing	13.4%	33,280	29,354	18,340	281,047	11,923	4,778	-	-	19,639	-	12,654	16,263	-581	23,976	144,265	686	10,272	8,984	-	-	8.00

GERN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
License fees and royalties	$ 237	$ 596	$ 1,393
Operating expenses:
Research and development	125,046	95,518	85,727
General and administrative	69,135	43,628	29,665
Total operating expenses	194,181	139,146	115,392
Loss from operations	(193,944)	(138,550)	(113,999)
Interest income	18,152	2,529	527
Interest expense	(8,312)	(6,882)	(3,740)
Other income , net	(23)	1,002	1,100
Net loss	$ (184,127)	$ (141,901)	$ (116,112)
Basic net loss per share	$ (0.32)	$ (0.37)	$ (0.35)
Diluted net loss per share	$ (0.32)	$ (0.37)	$ (0.35)
Shares used in computing basic net loss per share	570,645,405	380,784,846	327,631,814
Shares used in computing diluted net loss per share	570,645,405	380,784,846	327,631,814

GERN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 70,023	$ 56,845
Restricted cash	1,115	364
Marketable securities	263,676	115,901
Interest and other receivables	1,655	3,144
Prepaid and other current assets	4,879	3,992
Total current assets	341,348	180,246
Noncurrent marketable securities	43,298
Property and equipment, net	1,177	793
Operating leases, right-of-use assets	3,556	4,147
Deposits and other assets	4,697	5,389
Total assets	394,076	190,575
Current liabilities:
Accounts payable	6,161	10,190
Accrued compensation and benefits	13,759	11,534
Operating lease liabilities	949	925
Debt	46,893	20,945
Accrued liabilities	40,308	33,100
Total current liabilities	108,070	76,694
Noncurrent operating lease liabilities	3,006	3,671
Noncurrent debt	35,051	30,212
Total liabilities	146,127	110,577
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.001 par value; 1,350,000,000 shares authorized; 544,912,215 and 390,262,524 shares issued and outstanding at December 31, 2023 and 2022, respectively	545	390
Additional paid-in capital	1,844,988	1,493,469
Accumulated deficit	(1,597,769)	(1,413,642)
Accumulated other comprehensive loss	185	(219)
Total stockholders' equity	247,949	79,998
Total liabilities and stockholders' equity	$ 394,076	$ 190,575

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

CEO	Dr. John A. Scarlett M.D.
WEBSITE	geron.com
INDUSTRY	Biotechnology
EMPLOYEES	107

Geron Corp Frequently Asked Questions

What is the ticker symbol for Geron Corp? What does GERN stand for in stocks?

GERN is the stock ticker symbol of Geron Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Geron Corp (GERN)?

As of Mon Apr 15 2024, market cap of Geron Corp is 1.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GERN stock?

You can check GERN's fair value in chart for subscribers.

What is the fair value of GERN stock?

You can check GERN's fair value in chart for subscribers. The fair value of Geron Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Geron Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GERN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Geron Corp a good stock to buy?

The fair value guage provides a quick view whether GERN is over valued or under valued. Whether Geron Corp is cheap or expensive depends on the assumptions which impact Geron Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GERN.

What is Geron Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, GERN's PE ratio (Price to Earnings) is -10.2 and Price to Sales (PS) ratio is 7.93 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GERN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Geron Corp's stock?

In the past 10 years, Geron Corp has provided 0.065 (multiply by 100 for percentage) rate of return.